MOBIDIAG-LTD.
Mobidiag Ltd, a Finnish molecular diagnostics company, today announced the issuance of two new patents complementing the Australian Patent n°2010247321 obtained in June 2016: US Patent n°9593381 and Japanese Patent n°6054178 covering a method and a kit for detecting antibiotic resistant bacteria, and more specifically, screening for carbapenemase genes causing carbapenem resistance in bacteria.
“At Mobidiag, we have been developing fast and reliable tests for the detection of infectious diseases, including antibiotic resistance with our Amplidiag® Carba+VRE kit and wider panels soon to come. These new additions to Mobidiag’s intellectual property are key in our global strategy and definitely strengthen our commitment towards the fight against antibiotic resistance, a major worldwide health concern nowadays” said Tuomas Tenkanen, CEO at Mobidiag.
With an estimated 10 million deaths a year by 20501 , antimicrobial resistance is currently one of the biggest threats to global health. Mistreatment and excessive use of antibiotics have given rise to multidrug resistant organisms, also called superbugs, making antibiotics less and less effective. New diagnostic tools are then needed to support early decision making prior to any treatment delivery. Reliable and fast diagnostics would 1- ensure patient care and safety by detecting infection type allowing selection of the appropriate treatment with or without antibiotics and 2- detecting rapidly superbacteria to isolate infected patients, treat them accordingly and avoid infection spreading.
1 Jim O’Neill et al . (May 2016). Tackling drug-resistant infections globally: Final report and Recommendations, The Review on Antimicrobial Resistance, p.11
About Amplidiag® CarbaR+VRE (CE-IVD)
Amplidiag® CarbaR+VRE
is a molecular test allowing detection of 9 groups of the most important
carbapenemase-producing organisms. These bacteria may cause multiple
antibiotics to perform inefficiently, which in turn can lead to serious
infections, particularly in healthcare settings. This multiplex PCR test
gives results within a few hours directly from pure culture samples as
opposed to days with current culture-based screening methods.
About Mobidiag Ltd.
Established in 2000, Mobidiag develops
innovative solutions to advance the diagnosis of infectious diseases and
serves the European clinical diagnostics market since 2008. Mobidiag is
headquartered in Espoo, Finland, with a subsidiary in Paris, France.
Mobidiag
addresses both high to medium volume screening with the new Amplidiag®
Easy platform, bringing the Amplidiag® suite further by automating the
workflow from sample to results, and the upcoming Novodiag® platform &
associated panels for a fully automated solution and suitable for
smaller volumes and labs. Visit www.mobidiag.com
.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170314006174/en/
Contact:
Mobidiag Ltd.
Tuomas Tenkanen, +358 505534980
tuomas.tenkanen@mobidiag.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CA-LASERFICHE25.4.2024 16:31:29 CEST | Press release
Digital Transformation’s Next Era: Generative AI and Laserfiche 12 at 2024 Empower Conference
ALPHA-BLUE-OCEAN25.4.2024 16:01:28 CEST | Press release
Alpha Blue Ocean Group and Europlasma, Expert in Depollution Solutions, Announce the Signing of a New €30 Million Financing Agreement
CT-INTERACTIVE-BROKERS25.4.2024 16:01:28 CEST | Press release
Interactive Brokers Announces Extended Trading Hours for US Treasury Bonds
VT-CANNATROL25.4.2024 14:04:26 CEST | Press release
Cannatrol, Creators of Breakthrough Postharvest Cannabis Technology, Receive Two European Patent Approvals
CA-VISA25.4.2024 14:01:36 CEST | Press release
Visa Joins AWS Partner Network to Help Simplify Global Digital Payments
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom